Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(13%)
Results Posted
67%(2 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
4
50%
Ph phase_2
2
25%
Ph phase_4
1
13%
Ph phase_3
1
13%

Phase Distribution

4

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
4(50.0%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
1(12.5%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(3)
Terminated(3)
Other(1)

Detailed Status

Completed3
Withdrawn2
Recruiting1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (50.0%)
Phase 22 (25.0%)
Phase 31 (12.5%)
Phase 41 (12.5%)

Trials by Status

recruiting113%
unknown113%
completed338%
withdrawn225%
terminated113%

Recent Activity

1 active trials
Showing 5 of 8
recruitingphase_2

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

NCT06195306
withdrawnphase_1

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

NCT03167177
withdrawnphase_1

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

NCT03167164
completedphase_2

Fish Oil Study for High Triglyceride Levels in Children

NCT00915902
completedphase_3

Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation

NCT00402363
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06195306Phase 2

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Recruiting
NCT03167177Phase 1

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn
NCT03167164Phase 1

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Withdrawn
NCT00915902Phase 2

Fish Oil Study for High Triglyceride Levels in Children

Completed
NCT00402363Phase 3

Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation

Completed
NCT00694746Phase 1

Study of Fish Oil to Reduce ALT Levels in Adolescents

Terminated
NCT01431690Phase 1

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

Completed
NCT00934219Phase 4

Triglyceride Lowering Study

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8